FKFlorentia Kaguelidou

Florentia Kaguelidou

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Florentia Kaguelidou has a total of 198 co-authors. Here are the top co-authors by number of shared publications:

  • Zaba Valtuille

    Center of Clinical Investigations, APHP.Nord, INSERM CIC1426, Robert Debré University Hospital , Paris

    6 shared publications
  • Hugo Peyre

    Excellence Centre for Autism and Neurodevelopmental disorders CeAND, Autism Reference Centre of Languedoc-Roussillon CRA-LR, Montpellier University Hospital, MUSE University, Montpellier, France

    5 shared publications
  • Laurent Chouchana

    Pharmacovigilance Regional Centre, Pharmacology Department, Cochin Hospital, APHP UMR1343 INSERM Université Paris Cité Paris France

    5 shared publications
  • Richard Delorme

    Department of Child and Adolescent Psychiatry, APHP.Nord, Robert Debré University Hospital, Paris Cité University, Paris, France

    5 shared publications
  • Adriana Ceci

    Fondazione per la Ricerca Farmacologica Gianni Benzi Onlus, Via Giulio Petroni 91/D, 70124 Bari, Italy

    4 shared publications
  • Jean-Marc Treluyer

    4 shared publications

Latest Publications

  • Spatial and seasonal patterns of pediatric idiopathic nephrotic syndrome in France

    by Cyrielle Parmentier, Florian Bayer, Elodie Merieau, Zaba Valtuille, Tim Ulinski, Charlotte Duneton, Florentia Kaguelidou, Claire Dossier, Julien Hogan

    Background and hypothesis: Idiopathic nephrotic syndrome (INS) is the most frequent glomerular disease in children, yet robust population-based data remain limited, particularly at the national level. We hypothesized that nationwide health data could provide reliable estimates of INS incidence and help characterize its spatial and temporal patterns. Methods: We conducted a nationwide cohort study using the French National Health Data System (SNDS), which covers nearly the entire population and captures hospital, emergency, and day-care activity. Children and adolescents <20 years with an in-hospital diagnosis of nephrotic syndrome between 2013 and 2023 were identified and validated through oral corticosteroid (OCS) dispensing. A 7-year wash-out period excluded prevalent cases. We estimated national incidence, identified spatial clusters using SaTScan, and assessed seasonality using Seasonal-Trend Decomposition (STL). Results: The analytic cohort included 4475 incident INS cases (62% boys; median age, 6 years). External validation against the NEPHROVIR cohort showed 84% sensitivity with comparable age and sex distributions. The national mean annual incidence was 2.49 per 100 000 person-years [95% confidence intervals (CI), 2.41–2.56], higher in boys (3.05) than in girls (1.93). Two significant high-risk clusters were identified: the Paris area [standardized incidence ratio (SIR), 1.59; P < 0.001] and south-western France (SIR, 1.34; P < 0.001). These clusters were consistent across sensitivity analyses. STL analysis revealed a reproducible bimodal seasonal pattern with peaks in winter and late spring. Conclusions: This nationwide study provides robust estimates of pediatric INS incidence in France and identifies geographic clustering and consistent seasonal patterns, suggesting a potential role for environmental and infectious factors.

  • Open Access

    Trends in Psychotropic Medication and Polypharmacy Exposure among Pregnant Women in France: Nationwide Cross-Sectional Study, 2010-2024

    by Constance Bordet, Lucie Noe, Mathis Collier, Laurent Chouchana, Jean-Marc Treluyer, Nhung Th Trinh, Justine Benevent, Felicia Joinau-Zoulovits, Abd-El-Kader Ait Tayeb, Emmanuel Chazard, et al.

    Background: Data on psychotropic medication exposure and polypharmacy during pregnancy remain scarce, although monitoring trends is essential to guide clinical practice and public health policies.Methods: This cross-sectional study used data from the French National Health Data System between Jan. 2010 and Dec. 2024. Annual prevalence of psychotropic medication exposure and polypharmacy during pregnancy was defined as the proportion of pregnancies exposed to at least one psychotropic medication or two psychotropic medications, respectively, divided by the total number of pregnancies ending in that year. Analyses were stratified by maternal age and psychotropic class. Joinpoint regression assessed temporal trends and identified time points where significant shifts occurred.Findings: We identified 596,458 (5·9%) pregnancies exposed to any psychotropic medication and 143,395 (1·4%) to psychotropic polypharmacy. Anxiolytics (77·4% of pregnancies), antidepressants (31·5%), and hypnotics (10·1%) were the most frequently dispensed. Overall exposure to psychotropic medications during pregnancy declined, mainly driven by reductions to anxiolytics and hypnotics. In contrast, antidepressant exposure increased, alongside that of antipsychotics, lithium, and psychostimulants. Three time segments with distinct trends were identified for psychotropic exposure during pregnancy: 2010-2016 (annual percent change: -1·1%; 95%CI, -1·5 to -0·5%), 2016-2019 (-5·9%; -6·7 to -4·5%), and 2019-2024 (2·9%; 2·2 to 3·7%); and in polypharmacy exposure: 2010-2016 (-0·9%; -1·3 to -0·4%), 2016-2020 (-3·9%; -4·8 to -3·3%), and 2020-2024 (6·6%; 5·9 to 7·2%). After 2019-2020, psychotropic exposure increased most in women aged ≤24 years (3·0% vs 2·8% for those aged 25-34 years and 2·0% for those aged ≥35 years), as did polypharmacy (10·3% vs 6·4% and 2·9%, respectively). Interpretation: The expansion of mental health screening and greater acceptance of psychotropic treatment by both healthcare providers and women could have contributed to accelerating trends in exposure during pregnancy. Youngest mothers, who showed the steepest increases, and the rising prevalence of polypharmacy warrant close monitoring.

  • Optimiser l'évaluation des médicaments en néonatologie : l'exemple des médicaments anti-infectieux

    by Florentia Kaguelidou

    La population néonatale est la population pédiatrique la plus vulnérable car immature et celle ayant probablement les besoins en médicaments les plus importants, compte tenu de la spécificité des pathologies néonatales. Pour autant, un grand nombre de médicaments sont prescrits en dehors des conditions de leur AMM, ne permettant pas leur utilisation optimale. Cela est lié notamment aux difficultés de la recherche clinique chez le nouveau-né. L’objectif de cette thèse est d’analyser les différentes étapes de l’évaluation des médicaments chez le nouveau-né et de discuter les méthodes permettant de les optimiser, en centrant la réflexion sur la classe des médicaments anti-infectieux. En effet, ces médicaments sont parmi les plus prescrits hors AMM chez le nouveau-né, prématuré et à terme, bien qu’ils soient commercialisés depuis de nombreuses années. Nos travaux ont porté sur les différentes étapes de leur évaluation, illustrées chacune par un exemple. 1) Analyse des spécificités de la population néonatale et des pratiques d’utilisation des médicaments, illustrées par l’enquête Européenne sur l’utilisation de la ciprofloxacine et du fluconazole dans les unités de soins intensifs néonatales. Cette enquête a mis en évidence la grande variabilité des pratiques entre les pays mais aussi entre les centres d’un même pays, 2) Recueil et analyse des données disponibles, illustrés par la revue exhaustive de la littérature sur l’utilisation de la ciprofloxacine pour le traitement d’infections néonatales à germes Gram négatif, 3) Détermination de la posologie adéquate. L’implémentation d’outils de modélisation et de simulation de données est particulièrement préconisée chez le nouveau-né. La validation de ces modèles est importante, illustrée ici par une étude d’évaluation externe des modèles pharmacocinétiques de population de la vancomycine chez le nouveau-né. 4) Conception et réalisation des essais cliniques illustrées par l’exemple du développement clinique de la ciprofloxacine en néonatologie. La revue de la littérature sur les essais contrôlés randomisés évaluant les antibiotiques chez le nouveau-né a montré que la qualité des résultats de ces essais était globalement faible. L’analyse des obstacles à leur réalisation a permis de discuter les alternatives méthodologiques afin de contourner les difficultés pratiques, cliniques et éthiques sous-jacentes.

  • Open Access

    Obinutuzumab versus Rituximab to maintain remission in children with steroid-dependent and frequently relapsing nephrotic syndrome: the OBIRINS study protocol, a double-blind randomised controlled trial

    by Claire Dossier, Anne-Laure Sellier-Leclerc, Thomas Simon, Cyrielle Parmentier, Olivia Boyer, Charlotte Samaille, Marc Fila, Gwenaelle Roussey-Kesler, Marie Magnavacca, Yannis Chartier, et al.

    Introduction: There is an unmet clinical need for the development of novel treatment strategies to improve the outcome of children with frequent relapsing or steroid-dependent nephrotic syndrome. Obinutuzumab (OBI) is a second-generation anti-CD20 monoclonal antibody that has demonstrated its superiority to rituximab (RTX) in vitro and in vivo. Our assumption is that a single infusion of low-dose OBI will induce longer B-cell depletion, longer sustained remission and reduce the frequency of relapses and the use of oral immunosuppressors compared with a single infusion of RTX. Methods and analysis: We conduct a double-blind, multicentre, randomised, parallel group in a 1:1 ratio controlled trial. In the experimental group, patients receive 1 infusion of OBI (300 mg/1.73 m 2 ) and in the control group, the patients receive 1 infusion of RTX (375 mg/m 2 ). The primary outcome of the study is the occurrence of the first relapse within 12 months following the initiation of treatment and secondary outcomes include the time to first relapse, the total number of relapses during the 24-month follow-up period, and any adverse events such as infusion-related complications, infectious complications, hypogammaglobulinaemia and neutropenia. Ethics and dissemination: The study has been approved by the ethics committee (Comité de Protection des Personnes) of Sud Méditerrannée 2 and authorised by the French drug regulatory agency (Agence Nationale de Sécurité du Médicament et des Produits de Santé). Results of the primary study and the secondary aims will be disseminated through peer-reviewed publications. Trial registration number: NCT05786768 . Eudract N°: 2022-003336-59.


  • Trends of Opioids and Nefopam Use Among French Children: A Population-Based Study From 2009 to 2023

    by Sandrella Hamdan, Pierre Pinson, Jean-Marc Tréluyer, Florentia Kaguelidou, Laurent Chouchana, Violaine Smail-Faugeron

    Background and objectives Effective pain management in children is a public health priority, while opioid-related risks remain a major concern. The aim of the present study was to describe trends of opioids and nefopam use in children in France. Methods We conducted a nationwide drug utilization study using the French National Health Data System (SNDS), covering > 98% of the French population. All children with at least one prescription for a weak opioid, strong opioid, or nefopam between 2009 and 2023 were included. Annual prevalence of use was estimated per 1000 children, stratified by age group (< 2, 2–6, 7–11, 12–17 years). Joinpoint regression was used to analyze temporal trends. Contraindicated use was defined according to age restrictions in marketing authorizations. Results Overall, 4,443,648 children were included in the study. Overall prevalence of analgesic use increased from 22.7‰ in 2009 to 27.4‰ in 2023, mainly driven by weak opioids (26.3‰ in 2023). In 2023, tramadol was the most prescribed weak opioid (13.5‰), followed by codeine (10.1‰). Nefopam use, contraindicated for use under 15 years of age, rose sharply to 1.9‰. Strong opioids, notably morphine and oxycodone, steadily increased but remained low (0.4‰ and 0.08‰, respectively). Most children receiving prescriptions were aged 12–17 years, although weak opioid use declined in this group over the study period. In contrast, children aged 2–6 years showed a fivefold increase in overall analgesic use, driven almost entirely by tramadol, which increased eightfold, while codeine use declined. Contraindicated use remained frequent for tramadol, codeine, opium powder, and nefopam, increasing as children approached the minimal approved age. Conclusion Tramadol was the most commonly prescribed opioid used in pediatric outpatients in France in 2023, followed by codeine. Tramadol off-label use steadily increased, whereas codeine off-label use decreased. The sharp rise in tramadol, especially in children aged 2–6 years, and nefopam prescribing, together with increasing morphine and oxycodone use, in association with frequent contraindicated use, underscores the need for enhanced surveillance and pediatric-specific safety data.

  • Impact of RSV Immunization on the Rate of Pediatric Acute Otitis Media: A Time-series Analysis

    by Inès Fafi, Corinne Levy, André Birgy, Stéphane Bechet, Andreas Werner, Christophe Batard, Bruno Franji, Yannis Lassoued, Fabienne Cahn Sellem, Romain Basmaci, et al.

    Background: Acute otitis media (AOM) is the leading cause of antibiotic prescription in children. Respiratory syncytial virus (RSV) is suspected to play an important role in AOM. The aim of this study was to estimate the impact of RSV immunization on the rate of subsequent AOM in children, as this effect remains unknown. Methods: We conducted an interrupted time-series analysis based on a French network involving 110 ambulatory pediatricians, trained in pediatric infectious diseases (PARI network). All ambulatory visits for AOM, from June 2017 to February 2025 were included. The main outcome was the monthly rate of pediatric ambulatory visits for AOM in infants aged < 12 months per 1000 pediatric ambulatory visits over time, assessed by a seasonally adjusted quasi-Poisson regression model. Bronchiolitis and urinary tract infections (UTI) were analyzed over the same period, as positive and negative controls, respectively. Results: We included 70 452 cases of AOM, 13 284 bronchiolitis and 814 UTI. The rate of AOM per 1000 visits in infants aged < 12 months significantly decreased after RSV immunization implementation (−23.7%, 95% CI −37.6 to −9.7, P = .0014), whereas no significant change was observed in older age groups. We observed similar trends for bronchiolitis. The monthly rate of UTI did not significantly decrease. Conclusions: RSV immunization led to a strong reduction of AOM rate in infants aged < 12 months. Beyond its efficacy in preventing RSV-related lower respiratory infections in infants aged < 12 months, RSV immunization may contribute to reduce the burden of AOM in children.


  • Open Access

    The hidden pandemic: changes in outpatient mental health care among French children and adolescents

    by Zaba Valtuille, Vincent Trebossen, Naim Ouldali, Michael Huguet, Hugo Peyre, Richard Delorme, Florentia Kaguelidou

    The COVID-19 pandemic significantly worsened mental health (MH) challenges among young people. We aimed to assess changes in mental health-related outpatient care before and after the onset of the pandemic. In this nationwide cross-sectional study, we retrieved visits to general practitioners (GP) resulting in the coding of a MH disorder and/or the prescribing of any psychotropic medication for children aged 6 to 17 years, from January 1, 2016 to May 31, 2022 in France. Interrupted time series analysis of monthly rates of MH-related outpatient visits (per 100,000) was conducted to assess changes in trends overall and by age and sex group (girls/boys- 6 to 11 years; girls/boys- 12 to 17 years). Rate ratios (RR) were also calculated to compare estimated rates after the pandemic onset with expected rates. In total, 5,271,958 MH-related outpatient visits were analyzed. We noted an immediate decrease of the outpatient visit rate by 30.8% in the initial pandemic period (March-May 2020). Hereafter, visit rates increased by 0.4% per month, eventually exceeding expected levels by 6% overall. Notably, outpatient visit rates for adolescent girls (12-17 years) rose 20% above expected levels, while rates for younger girls (6-11 years) declined by 6%. Trends remained stable for other age-sex groups. These findings indicate a persistent increase in outpatient mental healthcare use in children, especially adolescent girls, more than two years after the pandemic onset. Future research should explore the factors contributing to the increased mental health burden in adolescent girls and the potential resilience observed in boys.

  • Open Access

    Evaluation of Methods for Joinpoint Analysis of Time Series Using Simulated and Real-World Data

    by Lucie Noé, Zaba Valtuille, Emilie Lanoy, Sandrine Katsahian, Florentia Kaguelidou


  • Open Access

    Descriptive Analysis of Pediatric Studies Included in the European Union Post-Authorization Study Register from 2010 to 2023

    by Annalisa Landi, Giorgio Reggiardo, Antonella Didio, Annunziata D’ercole, Adriana Ceci, Grace Shalom Govere, Donato Bonifazi, Fedele Bonifazi, Salvatore Crisafulli, Gianluca Trifirò, et al.

    Background/Objectives: This work aimed to analyze pediatric Post-Authorization Studies (PASs) registered in the European Union electronic Register of Post-Authorization Studies (EU PAS Register) from September 2010 to April 2023 to identify trends in terms of timing, age groups, and therapeutic areas and to discuss pediatric specificities and sources of funding for the PASs. Methods: A screening process identified PASs conducted exclusively on the pediatric population, and instructions were provided to ensure standardized data collection from the EU PAS Register. A univariate linear regression descriptive analysis was performed to assess trends over time, while a multivariate linear regression analysis helped explore additional characteristics of these studies. Results: Of the 2574 PASs extracted from the EU PAS Registry, 165 were included in this analysis. The majority of pediatric PASs were observational studies (86%), and most of them utilized secondary data (53%). The annual number of PASs increased significantly between 2010 and 2023. As envisaged, the largest part was funded by pharmaceutical companies (62%). Anti-infectives for systemic uses (25%), medicines for the nervous system (18%), and antineoplastic and immunomodulating agents (15%) resulted in the most studied drugs. Conclusions: Our findings show that post-marketing observational research in pediatric populations has increased over time. Nevertheless, industry–academia collaboration should be encouraged, and regulatory guidance is needed to prioritize research in areas of unmet therapeutic need.